Are we prepared to deal with the Alzheimer's disease pandemic?
Holtzman
J L
JL
Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA. holtz003@umn.edu
D000375:Aging / Q000473:pathology*; D000544:Alzheimer Disease / Q000453:epidemiology* / Q000473:pathology* / Q000628:therapy; D023582:Alzheimer Vaccines / Q000627:therapeutic use; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D004196:Disease Outbreaks; D005480:Flurbiprofen / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D053764:Presenilin-1 / Q000235:genetics; D014481:United States / Q000453:epidemiology
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D053764:Presenilin-1; C505522:tarenflurbil; D005480:Flurbiprofen